Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1293933.RAHpQAc2442HKLy7LkBvS-ha8itBD1hsGvSU9YtS_mvZo130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1293933.RAHpQAc2442HKLy7LkBvS-ha8itBD1hsGvSU9YtS_mvZo130_assertion type Assertion NP1293933.RAHpQAc2442HKLy7LkBvS-ha8itBD1hsGvSU9YtS_mvZo130_head.
- NP1293933.RAHpQAc2442HKLy7LkBvS-ha8itBD1hsGvSU9YtS_mvZo130_assertion description "[As such, CALR first, followed by MPL if CALR is absent, mutation screening is appropriate in the diagnostic work-up of JAK2-unmutated ET but does not replace the need for BM morphologic examination in (1) confirming the diagnosis in triple-negative ET and (2) distinguishing ET from other myeloproliferative neoplasms that share the same mutations, including masked PV and early/prefibrotic myelofibrosis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1293933.RAHpQAc2442HKLy7LkBvS-ha8itBD1hsGvSU9YtS_mvZo130_provenance.
- NP1293933.RAHpQAc2442HKLy7LkBvS-ha8itBD1hsGvSU9YtS_mvZo130_assertion evidence source_evidence_literature NP1293933.RAHpQAc2442HKLy7LkBvS-ha8itBD1hsGvSU9YtS_mvZo130_provenance.
- NP1293933.RAHpQAc2442HKLy7LkBvS-ha8itBD1hsGvSU9YtS_mvZo130_assertion SIO_000772 26355403 NP1293933.RAHpQAc2442HKLy7LkBvS-ha8itBD1hsGvSU9YtS_mvZo130_provenance.
- NP1293933.RAHpQAc2442HKLy7LkBvS-ha8itBD1hsGvSU9YtS_mvZo130_assertion wasDerivedFrom befree-2016 NP1293933.RAHpQAc2442HKLy7LkBvS-ha8itBD1hsGvSU9YtS_mvZo130_provenance.
- NP1293933.RAHpQAc2442HKLy7LkBvS-ha8itBD1hsGvSU9YtS_mvZo130_assertion wasGeneratedBy ECO_0000203 NP1293933.RAHpQAc2442HKLy7LkBvS-ha8itBD1hsGvSU9YtS_mvZo130_provenance.